Marcia Cruz-Correa, Chief Medical Officer at PanOncology Trials and Medical Director of Doctors Center Hospital Orlando Health, shared a post on LinkedIn:
“Honored to have participated in the educational videos for the global RCT for advanced Gastric/Gastroesophageal Junction Adenocarcinoma (Rationale-305) and RCT for Esophageal Squamous Cell cancers (Rationale-306).
These educational videos summarize the efficacy outcomes of Tizlelizumab (Tevimbra) as first-line therapy for GC/GEJ adenoCA, highlighting the increase in overall survival and progression-free survival for all study populations, including patients with peritoneal metastasis.
Our team of investigators at PanOncology Trials contributed to Rationale-305, impacting the outcome of this newly FDA-approved and NCCN-preferred regimen for patients with advanced GI cancers and tumor PD-L1 >=1 biomarker.
Thank you for the opportunity and all leaders who collaborated to make this happen. It’s a wrap!”
You can also read: Tislelizumab (Tevimbra): Uses in Cancer, Side Effects, Dosage, Expectations, and More
